Young adults with chronic pain: outcomes of a pilot program to meet development needs

2018 ◽  
Vol 19 (3) ◽  
pp. S36
Author(s):  
D. Luedtke ◽  
W. Gilliam ◽  
M. Evans ◽  
J. Sperry ◽  
C. Luedtke ◽  
...  
2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Henrik Bjarke Vaegter ◽  
Mette Terp Høybye ◽  
Frederik Hjorth Bergen ◽  
Christine E. Parsons

Abstract Objectives Sleep disturbances are highly prevalent in patients with chronic pain. However, the majority of studies to date examining sleep disturbances in patients with chronic pain have been population-based cross-sectional studies. The aims of this study were to 1) examine the frequency of sleep disturbances in patients referred to two interdisciplinary chronic pain clinics in Denmark, 2) explore associations between sleep disturbances and pain intensity, disability and quality of life at baseline and follow-up, and 3) explore whether changes in sleep quality mediated the relationships between pain outcomes at baseline and pain outcomes at follow-up. Methods We carried out a longitudinal observational study, examining patients enrolled in two chronic pain clinics assessed at baseline (n=2,531) and post-treatment follow-up (n=657). Patients reported on their sleep disturbances using the sleep quality subscale of the Karolinska Sleep Questionnaire (KSQ), their pain intensity using 0–10 numerical rating scales, their pain-related disability using the Pain Disability Index (PDI), and quality of life using the EuroQol-VAS scale. The average time between baseline and follow-up was 207 days (SD=154). Results At baseline, the majority of patients reported frequent sleep disturbances. We found a significant association at baseline between self-reported sleep disturbances and pain intensity, pain-related disability, and quality of life, where greater sleep disturbance was associated with poorer outcomes. At follow-up, patients reported significant improvements across all pain and sleep outcomes. In two mediation models, we showed that changes in sleep disturbances from baseline to follow-up were significantly associated with (i) pain intensity at follow-up, and (ii) pain disability at follow-up. However, baseline pain intensity and disability scores were not associated with changes in sleep disturbances and, we did not find evidence for significant mediation of either pain outcome by changes in sleep disturbances. Conclusions Self-reported sleep disturbances were associated with pain outcomes at baseline and follow-up, with greater sleep disturbances associated with poorer pain outcomes. Changes in sleep quality did not mediate the relationships between baseline and follow-up scores for pain intensity and disability. These findings contribute to a growing body of evidence confirming an association between sleep and chronic pain experience, particularly suggestive of a sleep to pain link. Our data following patients after interdisciplinary treatment suggests that improved sleep is a marker for a better outcome after treatment.


2016 ◽  
Vol 34 (2) ◽  
pp. 395-408 ◽  
Author(s):  
Neel Mehta ◽  
Charles E. Inturrisi ◽  
Susan D. Horn ◽  
Lisa R. Witkin
Keyword(s):  

2015 ◽  
Vol 2 ◽  
pp. 765-772 ◽  
Author(s):  
Sabra L. Katz-Wise ◽  
Bethany Everett ◽  
Emily A. Scherer ◽  
Holly Gooding ◽  
Carly E. Milliren ◽  
...  

Pain Medicine ◽  
2018 ◽  
Vol 20 (3) ◽  
pp. 486-494 ◽  
Author(s):  
Dokyoung S You ◽  
Sergiu Albu ◽  
Hans Lisenbardt ◽  
Mary W Meagher

2022 ◽  
Vol 15 ◽  
Author(s):  
Nynke J. van den Hoogen ◽  
Erika K. Harding ◽  
Chloé E. D. Davidson ◽  
Tuan Trang

Chronic pain is a complex sensory, cognitive, and emotional experience that imposes a great personal, psychological, and socioeconomic burden on patients. An estimated 1.5 billion people worldwide are afflicted with chronic pain, which is often difficult to treat and may be resistant to the potent pain-relieving effects of opioid analgesics. Attention has therefore focused on advancing new pain therapies directed at the cannabinoid system because of its key role in pain modulation. Endocannabinoids and exogenous cannabinoids exert their actions primarily through Gi/o-protein coupled cannabinoid CB1 and CB2 receptors expressed throughout the nervous system. CB1 receptors are found at key nodes along the pain pathway and their activity gates both the sensory and affective components of pain. CB2 receptors are typically expressed at low levels on microglia, astrocytes, and peripheral immune cells. In chronic pain states, there is a marked increase in CB2 expression which modulates the activity of these central and peripheral immune cells with important consequences for the surrounding pain circuitry. Growing evidence indicate that interventions targeting CB1 or CB2 receptors improve pain outcomes in a variety of preclinical pain models. In this mini-review, we will highlight recent advances in understanding how cannabinoids modulate microglia function and its implications for cannabinoid-mediated analgesia, focusing on microglia-neuron interactions within the spinal nociceptive circuitry.


2017 ◽  
Vol 81 (10) ◽  
pp. S137 ◽  
Author(s):  
Sarah Linnstaedt ◽  
Shan Yu ◽  
Connie Chen ◽  
Michael Kurz ◽  
Claire Pearson ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document